Show simple item record

dc.contributor.authorCimadamore, Alessia
dc.contributor.authorGasparrini, Silvia
dc.contributor.authorMassari, Francesco
dc.contributor.authorSantoni, Matteo
dc.contributor.authorCheng, Liang
dc.contributor.authorLópez-Beltrán, Antonio
dc.contributor.authorScarpelli, Marina
dc.contributor.authorMontironi, Rodolfo
dc.date.accessioned2019-02-25T09:08:21Z
dc.date.available2019-02-25T09:08:21Z
dc.date.issued2019
dc.identifier.urihttp://hdl.handle.net/10396/17933
dc.description.abstractLiquid biopsy, based on the circulating tumor cells (CTCs) and cell-free nucleic acids has potential applications at multiple points throughout the natural course of cancer, from diagnosis to follow-up. The advantages of doing ctDNA assessment vs. tissue-based genomic profile are the minimal procedural risk, the possibility to serial testing in order to monitor disease-relapse and response to therapy over time and to reduce hospitalization costs during the entire process. However, some critical issues related to ctDNA assays should be taken into consideration. The sensitivity of ctDNA assays depends on the assessment technique and genetic platforms used, on tumor-organ, stage, tumor heterogeneity, tumor clonality. The specificity is usually very high, whereas the concordance with tumor-based biopsy is generally low. In patients with renal cell carcinoma (RCC), qualitative analyses of ctDNA have been performed with interesting results regarding selective pressure from therapy, therapeutic resistance, exceptional treatment response to everolimus and mutations associated with aggressive behavior. Quantitative analyses showed variations of ccfDNA levels at different tumor stage. Compared to CTC assay, ctDNA is more stable than cells and easier to isolate. Splice variants, information at single-cell level and functional assays along with proteomics, transcriptomics and metabolomics studies can be performed only in CTCs.es_ES
dc.format.mimetypeapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightshttps://creativecommons.org/licenses/by-nc-nd/4.0/es_ES
dc.sourceCancers 11(2), 196 (2019)es_ES
dc.subjectRenal cell carcinomaes_ES
dc.subjectCirculating DNAes_ES
dc.subjectCTCes_ES
dc.subjectDiagnosises_ES
dc.subjectFollow-upes_ES
dc.subjectGenetic alterationes_ES
dc.subjectTarget therapyes_ES
dc.titleEmerging Molecular Technologies in Renal Cell Carcinoma: Liquid Biopsyes_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttp://dx.doi.org/10.3390/cancers11020196es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/openAccesses_ES


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record